The combined effects of numerous single-letter changes in several genes could be used to predict a woman’s risk of developing the most common form of breast cancer – oestrogen-receptor-positive breast cancer. 07 September 2010
MorphoSys AG has announced a new proprietary development program against novel infectious disease targets. As part of this initiative, MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics. 03 September 2010
Cancer Research Technology has signed an agreement with Bayer Schering Pharma AG, Germany, to evaluate new leptin antagonist peptides as potential experimental treatments, initially in the area of gynaecological diseases, including cancer. 25 August 2010
Researchers have used a drug to reset and restart the 24 hour body clock of mice, which could eventually help with human difficulties including some psychiatric disorders, jet lag and the health impacts of shift work. 24 August 2010
Cancer Research Technology has signed a deal to provide biotech company ValiRx PLC with the global rights to develop a promising compound to treat hormone-resistant prostate cancer. 16 August 2010
A pilot clinical trial examining Marinomed’s antiviral nasal spray, which contains carrageenan, has indicated that it is effective as a treatment against the common cold. 12 August 2010
BICOLL GmbH and EMBL have announced the successful completion of a joint research project on the identification of active compounds as inhibitors of aurora kinases. 23 June 2010
The UK launch of Sativex®, GW Pharmaceuticals’ oromucosal spray for the treatment of spasticity caused by multiple sclerosis, has been announced. 21 June 2010
Research identifying a novel, early biomarker for insulin resistance and glucose intolerance in a non-diabetic population has now been published. 17 June 2010
Hearing loss charity, RNID, is travelling to Chicago to launch a special issue of Drug Discovery Today at BIO International, the world’s largest biotechnology conference. RNID will be exhibiting at booth number 4707 Produced in association with RNID and Fight for Sight, the publication highlights the exciting progress being made in developing treatments for hearing and vision loss. 23 April 2010
The 1st International Symposium on Deuterium Depletion will be held on 13–14 May 2010 in Budapest, Hungary, and will enable researchers and medical practitioners to get acquainted with deuterium depletion, a novel tool of submolecular medicine. 19 March 2010
A new preparation of an omega-3 polyunsaturated fatty acid found naturally in fish could offer hope for thousands of patients at risk of developing an inherited form of bowel cancer. 18 March 2010
Lowering triglyceride levels for at-risk patients: first patients enrolled in MARINE and ANCHOR Phase III clinical trials for AMR101. 12 January 2010
Chemicals found in cannabis could prove an effective treatment for the inflammatory bowel diseases ulcerative colitis and Crohn's disease, say scientists. 22 December 2009
The Children’s Hospital research team believes the discovery will lead to more accurate and efficient diagnosis. 17 December 2009
ThromboGenics NV announced recently that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) age-related macular degeneration. 15 December 2009
The Food and Drug Administration has approved the approval of Qutenza (capsaicin) 8% patch, a medicated skin patch that relieves the pain of post-herpetic neuralgia, a serious complication that can occur after a bout with shingles. 18 November 2009
Germany's Paul-Ehrlich-Institute approves clinical trial in rheumatoid arthritis patients. 09 November 2009
This will be the first evaluation of CureVac's RNActive® vaccine technology in humans. 05 November 2009
The new biological medicine Ilaris® (canakinumab) has been approved in the EU to treat adults and children as young as four years old with CAPS, a rare life-long auto-inflammatory disease. 30 October 2009
The U.S. Food and Drug Administration has approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukaemia, a slowly progressing cancer of the blood and bone marrow. 29 October 2009
New results have shown that the novel biological therapy ACZ885 (canakinumab) is significantly more effective than an injectable corticosteroid at reducing pain and preventing recurrent attacks or ‘flares’ in patients with hard-to-treat gout, one of the most painful forms of arthritis. 26 October 2009
Cancer Research UK scientists at the University of Southampton have developed a potential new antibody treatment that, in the laboratory, shows significantly increased survival from neuroblastoma, a form of childhood cancer that grows from undeveloped tissue of the nervous system. 09 October 2009
Sanofi-aventis announced recently that it has signed a binding agreement for the acquisition of Fovea Pharmaceuticals SA (‘Fovea‘), a privately held French research and development biopharmaceutical company, focused on ocular diseases. 05 October 2009
Scientists have uncovered what happens to biomimetic nanoparticles when they enter human cells. 28 September 2009
Findings could lead to new targets for drug discovery. 23 September 2009
A series of iron-binding agents to prevent Alzheimer’s disease has shown promising potential for getting into brain tissue. 14 September 2009
Two varieties of basil that are widely used in Ayurvedic medicine have been scientifically shown to reduce inflammation and swelling, suggesting that they could have potential in arthritis treatment. 10 September 2009
A recent article in Molecular Cancer Therapeutics shows the anticancer potential of an inhibitor of ubiquitin-specific protease 7 (USP7). 28 August 2009
Cleveland BioLabs, Inc. announced recently that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/421,918, titled ‘Modulating Apoptosis’. Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502. 26 August 2009
For the first time, scientists have used a genetically engineered ‘friendly’ bacterium to deliver a therapy. 21 August 2009
A new experimental treatment for multiple sclerosis completely reverses the devastating autoimmune disorder in mice and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal. 20 August 2009
New technology designed to analyze large numbers of novel marine microbes could lead to more efficient and greener ways to manufacture new drugs for conditions such as epilepsy, diabetes, and flu and other viruses, as well as improving the manufacture of other products, such as agrochemicals. 14 August 2009
A compound initially isolated from a soft coral (Capnella imbricata), collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain. 05 August 2009
Debiopharm Group and MSM Protein Technologies have announced the signature of an exclusive agreement for the development and commercialization of Debio 0929, an antibody targeting a G-protein-coupled receptor (GPCR) to be developed into a new oncology therapeutic drug. 30 July 2009
The biotechnology medicine Ilaris® (canakinumab) has been recommended for approval in the European Union to treat patients with the life-long and potentially fatal auto-inflammatory disease cryopyrin-associated periodic syndrome. 28 July 2009
Ablynx, a biopharmaceutical company focused on the discovery and development of Nanobodies, has announced recently that it has advanced ALX-0061, a new Nanobody-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases. 20 July 2009
Email Address
Password
Forgotten login?